For the PDGF pathway, a clinical study of 45 breast cancer patients treated with an aromatase inhibitor showed that the protein expression of PDGF receptor α and β in tumor was significantly increased at the point of relapse and the higher expression was correlated with shorter time to treatment failure [22]. The gene discussed is CYP19A1; the disease is breast cancer.